Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies
TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer's disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million ...
Fanny Sie, MaRS Innovation's head of imaging technologies, was quoted in Tanya Powley's article, "Printing whole organs remains a long way off," for the U.K.'s Financial Times on June 11, 2015, regarding the technology's potential to transform existing healthcare practices.
MI does wish to note that the article inaccurately attributes the PrintAlive device's development to MaRS Innovation; MI is working with the University of Toronto inventing team, led by Dr. Axel Gunther, to commercialize the device.
Here's a short excerpt:
Bioprinting could save pharmaceutical ...
MaRS Innovation today announced that Johnson & Johnson Innovation has expanded its collaboration with MaRS Innovation to identify and advance early-stage technologies of interest.
The announcement was made in advance of the 2015 BIO Convention, which takes place from June 15 to 18 in Philadelphia, PA. MaRS Innovation is participating as part of the Ontario delegation and will have kiosk space in the Ontario pavilion (#615).
This partnership was covered in BioCentury, GEN, PharmaBiz and FierceBiotech.
Earlier this year, Johnson & Johnson Innovation and ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation's president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals:
The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office ...
"The first disclosed grant under Merck & Co. Inc.'s Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin [a4b7,] inhibitors for inflammatory bowel disease," writes Michael J. Haas in SciBX's feature on the partnership, "Merck Encycles through Canada." The article appears in the publication's December 4, 2014 issue.
Read the Encycle press release that prompted this article.
The article explores the current grant partnership between Merck, Encycle Therapeutics, MaRS Innovation, the Institute for ...
Company's collaborative partnership with IRICoR, Université de Montréal and MaRS Innovation, funded by Merck Canada, to advance macrocycle drug
TORONTO and MONTREAL, Nov. 10, 2014 — Encycle Therapeutics Inc., a biotechnology start-up founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease.
This announcement was covered in SciBX, Drug Discovery ...
TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC).
Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company's founding investors.
This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity.
Today's financing builds on prior ...
Tech Transfer Tactics, the monthly newsletter for Tech Transfer Central.com, has published a feature highlighting MaRS Innovation's Technology Transfer & Scouting (MITTS) services to St. Michael's Hospital.
The interview explores the increase in disclosures and commercial activity achieved after MaRS Innovation began offering technology transfer services to the hospital, and was triggered by a July profile published on MaRS Innovation's website describing the collaborative working relationship between the two organizations.
The interview includes conversations with Sahail Shariff, commercialization manager in the MITTS division, ...
MaRS Innovation among founding partner CECRs; Accel-Rx will provide funds to new biotechnology start-ups emerging within MI's portfolio
VANCOUVER, BC (Aug. 25, 2014) –With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched.
Media coverage of this announcement: CBC's Inside Politics blog, IT Business ...